期刊文献+

聚合酶链反应-单链构象多态性技术检测瘢痕疙瘩成纤维细胞p53基因突变 被引量:2

Study of p53 gene mutation in fibroblasts of keloids using PCR-SSCP
下载PDF
导出
摘要 目的 :分析瘢痕疙瘩成纤维细胞p5 3基因突变高发区第 4~ 8外显子的突变及其意义。 方法 :取手术切除的瘢痕疙瘩和非增生瘢痕各 12例 ,分别采用相应正常皮肤对照 ,体外培养成纤维细胞 ,采用聚合酶链反应 单链构象多态性 (PCR SSCP)技术检测 p5 3基因的突变情况。  结果 :12例瘢痕疙瘩成纤维细胞标本中有 9例 p5 3基因外显子 4、5、6、7出现突变 ,非增生瘢痕标本和正常皮肤标本均未检出突变。 结论 :p5 3基因突变是瘢痕疙瘩形成和发展的重要因素之一。 Objective:To investigate the significance of exon 4-8 of p53 gene mutations in fibroblasts of keloids. Methods:Twelve keloid tissues, Twelve normal scar tissues and healthy skins were obtained from 24 patents with keloid or normal scar lesions. Using polymerase chain reaction-based single-stand conformational polymorphism (PCR-SSCP) to detect p53 gene mutations. Results:Mutations in the exon 4-7 of p53 gene were identified in 9 keloid fibroblast tissues. No p53 gene mutations were detected in normal scar and healthy skin samples of any of the patients. Conclusion:p53 gene mutations play an important role in the formation of keloids.
出处 《医学研究生学报》 CAS 2004年第3期256-258,共3页 Journal of Medical Postgraduates
关键词 P53基因 瘢痕疙瘩 基因突变 凋亡 聚合酶链反应-单链构象多态性 p53 gene Gene mutation Apoptosis Keloid PCR-SSCP
  • 相关文献

参考文献9

  • 1[1]Wu M, Bellas RE, Shen J et al. Roles of the tumor suppressor p53 and the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in receptor-mediated apoptosis of WEHI 231 B lymphoma cells[J]. J Exp Med,1998,187(10): 1671-1679.
  • 2[2]Cho Y, Gorina S, Jeffrey PD et al. Crystal structure of p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations[J]. Science, 1994,265(5170): 346-355.
  • 3[3]Peters AM, Kohfink B, Martin H et al. Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease[J]. SO: Exp-Hematol,1999,27(5): 868-874.
  • 4[4]Chang F, Syrjanen S, Kurvinen K. The p53 tumor suppressor gene as a common cellar target in human carcinogenesis[J]. Am J Gastroenterol, 1993,88(2): 174-186.
  • 5[5]Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene[J]. N Engl J Med, 1993,329(18): 1318-1327.
  • 6[6]Peli J, Schroter M, Rudaz C et al. Oncogenic ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas[J]. EMBO J, 1999,18(7): 1824-1831.
  • 7[7]Subbotin V, Sun H, Aitouche A et al. Marked mitigation of transplant vascular sclerosis in FasLgld (CD95L) mutant recipients. The role of alloantibodies in the development of chronic rejection[J]. Transplantation,1999,67(10): 1295-1300.
  • 8[8]Garner WL, Kamiol S, Rodriguez JL et al. Phenotypic differences in cytokine responsiveness of hypertrophic scar versus normal demal fibroblasts[J]. J Invest Dermatol, 1993,101(6): 875-879.
  • 9[9]Hartmann A, Blaszyk H, Mcgovern RM et al. p53 gene mutation inside and outside of exons 5-8: the patterns differ in breast and other cancer[J]. Oncogene, 1995, 10(6): 681-684.

同被引文献14

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部